July 27, 2026

Colorectal Cancer Screening Blood Test Approved by FDA

The blood-based assay demonstrated 81% sensitivity for colorectal cancer in the PREEMPT CRC study.

Conexiant

July 23, 2026

Oral Shigella Vaccine Hits 89% Efficacy in Challenge Trial

An investigational oral Shigella sonnei vaccine showed robust protection against shigellosis in a phase 2 controlled human infection trial.

Conexiant

July 22, 2026

Medical Oddities: When AI Meets the Afterlife

Ghosts, germs, B cells, and brews—this week's research is anything but ordinary.

Conexiant

July 17, 2026

FDA Probes Taco Bell Cyclospora Outbreak

FDA's traceback investigation identified a single supplier of iceberg lettuce from Mexico. The agency has initiated product sampling, increased border screening, and said Taco Bell plans to stop using lettuce from the identified supplier.

Conexiant

July 16, 2026

A Sales Tax on Doctor Visits and Medicine? In Missouri, Some Worry

Voters will decide whether to expand lawmakers' authority to tax currently exempt healthcare goods and services, raising concerns about patient costs and healthcare access.

Kff Health News

July 16, 2026

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

Conexiant

July 15, 2026

Medical Oddities: Natural Doesn't Always Mean Safe

From the gym to the kitchen to romance, these studies challenge everyday assumptions.

Conexiant

July 14, 2026

Autism Spectrum Disorder Linked to Distinct Urine Metabolite Pattern

Researchers proposed a new autism spectrum disorder phenotype characterized by elevated urinary microbially derived metabolites.

Conexiant

July 13, 2026

Side Effects: Signals in Strange Places

From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.

Conexiant

July 06, 2026

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

Conexiant